Combinatorial drug therapy in cancer - New insights

Bhatia, Karanpreet Singh; Bhumika,; Das, Asmita

doi:10.1016/j.lfs.2020.118134

Cited by 53 publications

(39 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, it is possible that the complex mechanisms of AD pathogenesis in humans will require the simultaneous targeting of multiple molecules, including but not limited to GSK3. The strategy of combinatorial drug therapy is well-accepted in the treatment of cancer [ 245 , 246 , 247 ].…”

Section: The Enzymesmentioning

confidence: 99%

When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer’s and Huntington’s Disease

D’Mello¹

2021

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a mostly sporadic brain disorder characterized by cognitive decline resulting from selective neurodegeneration in the hippocampus and cerebral cortex whereas Huntington’s disease (HD) is a monogenic inherited disorder characterized by motor abnormalities and psychiatric disturbances resulting from selective neurodegeneration in the striatum. Although there have been numerous clinical trials for these diseases, they have been unsuccessful. Research conducted over the past three decades by a large number of laboratories has demonstrated that abnormal actions of common kinases play a key role in the pathogenesis of both AD and HD as well as several other neurodegenerative diseases. Prominent among these kinases are glycogen synthase kinase (GSK3), p38 mitogen-activated protein kinase (MAPK) and some of the cyclin-dependent kinases (CDKs). After a brief summary of the molecular and cell biology of AD and HD this review covers what is known about the role of these three groups of kinases in the brain and in the pathogenesis of the two neurodegenerative disorders. The potential of targeting GSK3, p38 MAPK and CDKS as effective therapeutics is also discussed as is a brief discussion on the utilization of recently developed drugs that simultaneously target two or all three of these groups of kinases. Multi-kinase inhibitors either by themselves or in combination with strategies currently being used such as immunotherapy or secretase inhibitors for AD and knockdown for HD could represent a more effective therapeutic approach for these fatal neurodegenerative diseases.

show abstract

Section: The Enzymesmentioning

confidence: 99%

When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer’s and Huntington’s Disease

D’Mello¹

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Given the toxic effects of chemotherapeutic agents on healthy cells due to the use of high doses especially in more advanced tumors, it has become necessary to investigate different methods to minimize these effects of the agents. In this context, low-dose combination of chemotherapeutics, additional natural compounds or certain antibiotics for treatments are considered new options that may be bene cial (Bhatia et al 2020). Particularly, antibiotics have been reported to have anticancer activities, similar to their effects on bacteria in treatment of bacterial infections (Bhattacharya et al 2015).…”

Section: Discussionmentioning

confidence: 99%

Levofloxacin Might be Safe to use for OSCC Patients

Aydemir

İplik

Ertuğrul

et al. 2021

Preprint

View full text Add to dashboard Cite

PurposeSince oral squamous cell carcinoma (OSCC) patients are exhausted against the powerful chemotherapies and radiotherapies after surgeries, therefore most of the studies still look for less toxic but effective alternatives with new ideas such as antibiotic combinations.MethodsThe antiproliferative and apoptotic outcomes of levofloxacin with cisplatin combination as well as their single usage were examined with WST-1, Caspase-3/BCA and Annexin-V methods on SCC-15 cells and on a healthy cell line (MRC-5).Results24h treatment of 50 mM single levofloxacin, 50 mM single cisplatin and 50 mM levofloxacin-cisplatin combination resulted in cell viability rates of SCC-15 cells as 90%, 67% and 80.8% respectively. Caspase-3 enzyme activity was enhanced 0.92-fold for single levofloxacin, 13.05-fold for single cisplatin and 9.73-fold for the combination of levofloxacin-cisplatin, the total apoptotic activity of single levofloxacin, single cisplatin and levofloxacin-cisplatin combination were observed as 4.88%, 21.14% and 16.21% respectively on SCC-15. Also MRC-5 were showed the lower toxicity than cancer cells via apoptosis.ConclusionLevofloxacin-cisplatin combination results have also ended up apoptotic results with less toxicity for cells than single cisplatin treatment. Therefore, our apoptotic findings suggest that the different dosage combinations with levofloxacin and cisplatin are necessary to understand the interaction for the treatment of tongue squamous cell carcinoma.

show abstract

“…Similarly, immunotherapeutic agents exert their action by interacting with specific cellular target antigens. The utility in the classification of therapeutic agents is often functional, toward greater comprehensibility and schematic representation [ 8 ].…”

Section: Genetic Therapy For Cancermentioning

confidence: 99%

“…Our experience with vaccines to prevent SARS-CoV-2 infection at an international level shows that they have a highly favorable safety profile, with some rare fatal events, considering the vast number of people vaccinated worldwide in the post-marketing setting. It must be highlighted that the biopharmaceutical technology that led, in a very short time, to the development of COVID vaccines (i.e., mRNA vaccines) comes from cancer immunotherapy research [ 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. Commonly detected toxic responses following cancer vaccine administration include myalgia, cough, chills, fever, pain at the injection site, asthenia, flu-like syndrome, and respiratory abnormalities [ 20 ,…”

Section: Pharmacovigilance and Adverse Drug Reactions (Adrs) Of Genet...mentioning

confidence: 99%

Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice

Orzetti

Tommasi

Bertola

et al. 2022

IJMS

View full text Add to dashboard Cite

The impressive advances in the knowledge of biomarkers and molecular targets has enabled significant progress in drug therapy for crucial diseases such as cancer. Specific areas of pharmacology have contributed to these therapeutic outcomes—mainly targeted therapy, immunomodulatory therapy, and gene therapy. This review focuses on the pharmacological profiles of these therapeutic classes and intends, on the one hand, to provide a systematic definition and, on the other, to highlight some aspects related to pharmacovigilance, namely the monitoring of safety and the identification of potential toxicities and adverse drug reactions. Although clinicians often consider pharmacovigilance a non-priority area, it highlights the risk/benefit ratio, an essential factor, especially for these advanced therapies, which represent the most innovative and promising horizon in oncology.

show abstract

Combinatorial drug therapy in cancer - New insights

Cited by 53 publications

References 82 publications

When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer’s and Huntington’s Disease

When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer’s and Huntington’s Disease

Levofloxacin Might be Safe to use for OSCC Patients

Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice

Contact Info

Product

Resources

About